Eli Lilly

News

Lilly stops promoting cancer drug after shock trial failure

Shares in Eli Lilly were down in early trading after the US drugmaker said its cancer drug Lartruvo failed to meet main survival goals in a late stage trial, prompting the company to stop p

News

Lilly's CEO looks to M&A, but not for CAR-T or gene therapie...

Eli Lilly’s CEO David Ricks could sign more deals to strengthen its pipeline of cancer drugs, but is leaving gene cell-based CAR-T oncology drugs and rare disease gene therapies for others

News

Closeup of X-ray photography of human brain

Lilly focuses on tau with AC Immune Alzheimer's R&D tie-up

Eli Lilly has paid $81m to develop drugs targeting aggregation of tau proteins associated with Alzheimer’s with Swiss biotech AC Immune, as focus shifts away from therapies targeting clumps

News

Novo Nordisk's diabetes pill clears cardiac safety hurdle

Novo Nordisk is set to file its daily semaglutide type 2 diabetes pill after it cleared a phase 3 trial assessing its cardiac safety, with results showing it also reduced risk of cardiovasc

News

Lilly files new class migraine drug with FDA

Eli Lilly has filed a new migraine drug, lasmiditan, with the US regulator, the first drug in its class to be reviewed as a treatment for the condition.

News